181 related articles for article (PubMed ID: 37220750)
21. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
22. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
24. Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer.
Jönsson JM; Bååth M; Björnheden I; Sahin ID; Måsbäck A; Hedenfalk I
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445465
[TBL] [Abstract][Full Text] [Related]
25. A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.
Kreuzinger C; Geroldinger A; Smeets D; Braicu EI; Sehouli J; Koller J; Wolf A; Darb-Esfahani S; Joehrens K; Vergote I; Vanderstichele A; Boeckx B; Lambrechts D; Gabra H; Wisman GBA; Trillsch F; Heinze G; Horvat R; Polterauer S; Berns E; Theillet C; Cacsire Castillo-Tong D
Clin Cancer Res; 2017 Dec; 23(24):7621-7632. PubMed ID: 28972047
[No Abstract] [Full Text] [Related]
26. Integrated weighted gene co-expression network analysis reveals biomarkers associated with prognosis of high-grade serous ovarian cancer.
Wang B; Chao S; Guo B
J Clin Lab Anal; 2022 Feb; 36(2):e24165. PubMed ID: 34997982
[TBL] [Abstract][Full Text] [Related]
27. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer.
Jin X; Du M; Wang Y; Wang Y; Lu Y; Xu C; Zhang X
J Ovarian Res; 2022 Dec; 15(1):134. PubMed ID: 36564848
[TBL] [Abstract][Full Text] [Related]
29. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.
Yang SYC; Lheureux S; Karakasis K; Burnier JV; Bruce JP; Clouthier DL; Danesh A; Quevedo R; Dowar M; Hanna Y; Li T; Lu L; Xu W; Clarke BA; Ohashi PS; Shaw PA; Pugh TJ; Oza AM
Genome Med; 2018 Oct; 10(1):81. PubMed ID: 30382883
[TBL] [Abstract][Full Text] [Related]
30. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
[TBL] [Abstract][Full Text] [Related]
31. Unraveling the Transcriptomic Signatures of Homologous Recombination Deficiency in Ovarian Cancers.
Lee JJ; Kang HJ; Kim SS; Charton C; Kim J; Lee JK
Adv Biol (Weinh); 2022 Dec; 6(12):e2200060. PubMed ID: 36116121
[TBL] [Abstract][Full Text] [Related]
32. BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.
Marchetti C; De Leo R; Musella A; D'Indinosante M; Capoluongo E; Minucci A; Benedetti Panici P; Scambia G; Fagotti A
Ann Surg Oncol; 2018 Nov; 25(12):3701-3708. PubMed ID: 30128899
[TBL] [Abstract][Full Text] [Related]
33. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S
Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993
[TBL] [Abstract][Full Text] [Related]
34. Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.
Geistlinger L; Oh S; Ramos M; Schiffer L; LaRue RS; Henzler CM; Munro SA; Daughters C; Nelson AC; Winterhoff BJ; Chang Z; Talukdar S; Shetty M; Mullany SA; Morgan M; Parmigiani G; Birrer MJ; Qin LX; Riester M; Starr TK; Waldron L
Cancer Res; 2020 Oct; 80(20):4335-4345. PubMed ID: 32747365
[TBL] [Abstract][Full Text] [Related]
35. Pathogenesis and heterogeneity of ovarian cancer.
Kroeger PT; Drapkin R
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):26-34. PubMed ID: 27898521
[TBL] [Abstract][Full Text] [Related]
36. Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer.
Lu H; Cunnea P; Nixon K; Rinne N; Aboagye EO; Fotopoulou C
Br J Cancer; 2021 Mar; 124(7):1286-1293. PubMed ID: 33473167
[TBL] [Abstract][Full Text] [Related]
37. Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
Bungsy M; Palmer MCL; Jeusset LM; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
Cancer Lett; 2021 Mar; 500():194-207. PubMed ID: 33290867
[TBL] [Abstract][Full Text] [Related]
38. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
39. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O
BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011
[TBL] [Abstract][Full Text] [Related]
40. Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.
Stanske M; Wienert S; Castillo-Tong DC; Kreuzinger C; Vergote I; Lambrechts S; Gabra H; Gourley C; Ganapathi RN; Kolaschinski I; Budczies J; Sehouli J; Ruscito I; Denkert C; Kulbe H; Schmitt W; Jöhrens K; Braicu I; Darb-Esfahani S
Neoplasia; 2018 Mar; 20(3):280-288. PubMed ID: 29466768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
